#ACR22 #ICYMI
#YIR

https://twitter.com/vksandhumd/status/1591452092082040834

RT @vksandhumd@twitter.com

IVIG in dermatomyositis (NEJM)
👉🏾RCT where IVIG vs PBO x 16 wk then OLE
👉🏾1' endpt: at least min improvement of 20 at 16wk
#ACR22 #ACRambassador

🐦🔗: https://twitter.com/vksandhumd/status/1591452092082040834

#ACR22 #ICYMI

#YIR

https://twitter.com/PanktiMehta24/status/1591453207523659777

RT @PanktiMehta24@twitter.com

Studies discussed in the #YearinRegiew session at #ACR22

🔸GLORIA trial
🔸ORAL surveillance
🔸MIRROR RCT
🔸Proderm trial
🔸Anti CD 19 CAR T in lupus
🔸 Obinitizumab, iberdomide & litifilimab phase 2 studies in SLE
🔸tocilizumab in polymyalgia rheumatica

#ACRambassador @ACRheum@twitter.com https://twitter.com/rheum_cat/status/1591446357432500225

🐦🔗: https://twitter.com/PanktiMehta24/status/1591453207523659777

#ACR22 #ICYMI
#YIR

https://twitter.com/Nellziade/status/1591452913314021378

RT @Nellziade@twitter.com

Year in Review
New mabs for COVID19
#ACR22 @ACRheum@twitter.com #ACRambassador
#RheumTwitter #MedTwitter

🐦🔗: https://twitter.com/Nellziade/status/1591452913314021378

#ACR22 #ICYMI

#YIR

https://twitter.com/AMollaeianMD/status/1591453531134955520

RT @AMollaeianMD@twitter.com

Year in review by Dr Carol Langford

✅ Be mindful of JAK inhibitor patients with high risk of CVD, cerebrovascular and peripheral vascular disease

✅ New indications for JAK inhibitors are being explored

✅ Lots new approvals in SpA realm esp PsA

#ACR22
#ACRambassador

🐦🔗: https://twitter.com/AMollaeianMD/status/1591453531134955520

#ACR22 #ICYMI
#YIR

https://twitter.com/Nellziade/status/1591452247963348993

RT @Nellziade@twitter.com

Year in Review
Tocilizumab in PMR
#ACR22 @ACRheum@twitter.com #ACRambassador
#RheumTwitter #MedTwitter

🐦🔗: https://twitter.com/Nellziade/status/1591452247963348993

Is fibrosis treatable? Reversible?

yes, at least in mice

a study of vaccine based immunotherapy

#ACR22 #YIR

RT @Reuma_Online_@twitter.com

¿Tratamiento de fibrosis? #ACR22
Uno de los grandes enemigos!
"Vacunación" podría prevenir aparición de fibrosis o reversible.

🐦🔗: https://twitter.com/Reuma_Online_/status/1591457399596281856

CD38 study: depletion of NAD and connection with disseminated infx in SLE

#ACR22 #YIR

RT @MayKazem@twitter.com

Basic Science Review #YearinReview #ACR22 Pathogenesis in #SLE: New molecular targets?
🧪TLR7 gain of function mutation 🧪CD38 up regulation and mitochondrial dysfunction

🐦🔗: https://twitter.com/MayKazem/status/1591456696140197888